MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of MoonLake Immunotherapeutics in a research report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith anticipates that the company will earn ($0.82) per share for the quarter. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics' FY2025 earnings at ($3.23) EPS, FY2026 earnings at ($4.30) EPS, FY2027 earnings at ($4.98) EPS and FY2028 earnings at $1.41 EPS.
A number of other analysts have also weighed in on the stock. Needham & Company LLC upped their target price on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. Finally, The Goldman Sachs Group decreased their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $83.20.
Check Out Our Latest Stock Report on MLTX
MoonLake Immunotherapeutics Trading Down 0.4 %
Shares of MLTX stock traded down $0.17 during trading on Monday, reaching $39.82. 134,832 shares of the company's stock traded hands, compared to its average volume of 341,686. The company has a market capitalization of $2.54 billion, a P/E ratio of -30.87 and a beta of 1.28. The firm's 50-day moving average is $45.74 and its 200 day moving average is $48.78. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $58.26.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09).
Hedge Funds Weigh In On MoonLake Immunotherapeutics
A number of institutional investors have recently made changes to their positions in the stock. FMR LLC increased its holdings in shares of MoonLake Immunotherapeutics by 28.1% in the 4th quarter. FMR LLC now owns 6,341,391 shares of the company's stock worth $343,386,000 after buying an additional 1,391,167 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of MoonLake Immunotherapeutics by 12.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company's stock worth $181,059,000 after buying an additional 363,394 shares during the last quarter. Paradigm Biocapital Advisors LP increased its holdings in shares of MoonLake Immunotherapeutics by 90.3% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,772,211 shares of the company's stock worth $95,965,000 after buying an additional 840,731 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of MoonLake Immunotherapeutics by 13.2% in the 4th quarter. Federated Hermes Inc. now owns 1,280,052 shares of the company's stock worth $69,315,000 after buying an additional 149,724 shares during the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of MoonLake Immunotherapeutics by 7.9% in the 4th quarter. Marshall Wace LLP now owns 1,245,299 shares of the company's stock worth $67,433,000 after buying an additional 90,914 shares during the last quarter. Institutional investors own 93.85% of the company's stock.
About MoonLake Immunotherapeutics
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
See Also
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
